Doug Cole
InvestorManaging Partner at Flagship Pioneering · Board director at Torque Therapeutics
Cambridge, Massachusetts
Writes $500K – $15M checks · typically $1.5M
Find your path to Doug
427 people in our graph can introduce you to Doug.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Elias Zerhouni to introduce you to Doug
You →Elias · together at Johns Hopkins Hospital (1986–1987) →Doug
Ask Jamie Chen to introduce you to Doug
You →Jamie · together at Johns Hopkins Hospital →Doug
Ask Sam Okafor to introduce you to Doug
You →Sam · 10 people · together at Flagship Pioneering →Doug
Sign up to find every way you can get introduced to Doug
- Your email: the people you already email who know Doug
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Doug
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
About
Douglas Cole, a former clinician-turned-investor, has spent over two decades conceiving and chairing platform biotech companies (Sigilon, Repertoire, Foghorn) focused on chromatin regulation, immune repertoire mapping and encapsulated cell therapies.
Contact· self-published, not guessed
Invests in
AgTechAI & Machine LearningBiotechClimate TechFoodTechHealthtech
Board director at Torque Therapeutics
Intro paths
In turn, Doug can intro founders to Torque Therapeutics's investors below.
Torque Therapeutics's investors · 1
Co-founders at Torque Therapeutics
Experience
- Flagship PioneeringManaging Partnercurrent2001 — present
- Vertex PharmaceuticalsProgram Executive1997 — 2001
- Cytotherapeutics, Inc.Medical Director1996 — 1997
- Massachusetts General HospitalAssistant in Neurology1992 — 1996
- Massachusetts General HospitalFellow in Neurology1990 — 1992
- Massachusetts General HospitalResident in Neurology1987 — 1990
- Harvard Medical SchoolInstructor in Neurology1992 — 1996
- Johns Hopkins HospitalIntern in Internal Medicine, Osler Medical Service1986 — 1987
Skills & more
From Doug's professional profile.
Investments
Investor
Agios PharmaceuticalsAvedroAVEO OncologyConcert PharmaceuticalsDenali TherapeuticsEditas MedicineEmpress TherapeuticsFoghorn TherapeuticsHarbinger HealthModernaQuanterixRepertoire Immune MedicinesSelecta BiosciencesSigilon TherapeuticsSyros PharmaceuticalsTetraphase PharmaceuticalsVesalius TherapeuticsYourBio Health
Per curated public sources.
Colleagues at Flagship Pioneering
Network1
Investors connected to Doug in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Doug Cole?
- Douglas Cole, a former clinician-turned-investor, has spent over two decades conceiving and chairing platform biotech companies (Sigilon, Repertoire, Foghorn) focused on chromatin regulation, immune repertoire mapping and encapsulated cell therapies.
- Where does Doug Cole work?
- Doug Cole is Managing Partner at Flagship Pioneering and Board director at Torque Therapeutics.
- What does Doug Cole invest in?
- Doug Cole invests in AgTech, AI & Machine Learning, Biotech, Climate Tech, FoodTech, Healthtech.
- What check size does Doug Cole write?
- Doug Cole typically writes checks of $500K – $15M.
- What companies has Doug Cole invested in?
- Investments tracked here include Agios Pharmaceuticals, Avedro, AVEO Oncology, Concert Pharmaceuticals, Denali Therapeutics, Editas Medicine, Empress Therapeutics, Foghorn Therapeutics, Harbinger Health, Moderna, Quanterix, Repertoire Immune Medicines, and 6 more.
- Where did Doug Cole go to school?
- Doug Cole studied at Dartmouth College (AB, English); University of Pennsylvania School of Medicine (Doctor of Medicine (M.D.)).
Same school
Also attended Dartmouth College766
+ 760 more
Also attended University of Pennsylvania School of Medicine61
+ 55 more
Shared employers
Also worked at Vertex Pharmaceuticals62
+ 56 more
Also worked at Massachusetts General Hospital150
+ 144 more
Also worked at Harvard Medical School361
+ 355 more
Also worked at Johns Hopkins Hospital31
+ 25 more











































